CelLBxHealth PLC (CLBX)
Industry Diagnostics & Research
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell
2.30p
Buy
2.50p
-0.25p (-9.43%)
Prices updated at 28 Oct 2025, 16:18 GMT
| Prices minimum 15 mins delay
Prices in GBX
ANGLE PLC is a commercially driven specialist medical diagnostic company with pioneering products in cancer diagnostics and foetal health. The Company's product includes Parsortix cell separation system.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2023 | 2024 |
|---|---|---|
| 2m | 3m | |
| 2m | 2m | |
| -20m | -15m | |
| -935.86 | -540.67 | |
| -20m | -14m | |
| -19m | -13m | |
| Sales, General and administrative | 382,000 | 455,000 |
| Interest expenses | 325,000 | 307,000 |
| Provision for income taxes | -1m | -804,000 |
| Operating expenses | 22m | 17m |
| Income before taxes | -22m | -15m |
| Net income available to common shareholders | -20m | -14m |
| -0.077175 | -0.0482 | |
| Net interest income | 138,000 | 89,000 |
| Advertising and promotion | - | - |
| Net investment income, net | -1m | 367,000 |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | -0.077175 | -0.0482 |
| Free cash flow per share | -0.0627 | -0.0478 |
| Book value/share | 0.1229 | 0.076 |
| Debt equity ratio | 0.170234 | 0.181552 |
Balance sheet
Year | 2023 | 2024 |
|---|---|---|
| Current assets | 21m | 16m |
| Current liabilities | 4m | 3m |
| Total capital | 23m | 18m |
| Total debt | 5m | 4m |
| Total equity | 23m | 18m |
| Total non current liabilities | - | - |
| Loans | - | - |
| Total assets | 31m | 25m |
| Total liabilities | - | - |
| Cash and cash equivalents | 16m | 10m |
| Common stock | 261m | 323m |
Cash flow
Year | 2023 | 2024 |
|---|---|---|
| Cash at beginning of period | 32m | 16m |
| Cash dividends paid | - | - |
| -15m | -14m | |
| Investments (gains) losses | -203,000 | -48,000 |
| 16m | 10m | |
| Net income | - | - |
| -14m | -13m | |
| -660,000 | -444,000 |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
